article Open AccessTop 1% cited
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
PLoS Medicine · 2005 · Vol. 2(1) · pp. e17–e17
William Pao✉(Memorial Sloan Kettering Cancer Center)Theresa Y. Wang(Memorial Sloan Kettering Cancer Center)Gregory J. Riely(Memorial Sloan Kettering Cancer Center)Vincent A. Miller(Memorial Sloan Kettering Cancer Center)Qiulu Pan(Memorial Sloan Kettering Cancer Center)Marc Ladanyi(Memorial Sloan Kettering Cancer Center)Maureen F. Zakowski(Memorial Sloan Kettering Cancer Center)Robert T. Heelan(Memorial Sloan Kettering Cancer Center)Mark G. Kris(Memorial Sloan Kettering Cancer Center)Harold Varmus(Memorial Sloan Kettering Cancer Center)
Abstract
Our results suggest that treatment decisions regarding use of these kinase inhibitors might be improved by determining the mutational status of both EGFR and KRAS.
Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesBiochemical and Molecular ResearchGefitinibKRASErlotinibEpidermal growth factor receptorLung cancerCancer researchAdenocarcinomaMedicineOncologyInternal medicine
MeSH terms
Erlotinib HydrochlorideGefitinibAdenocarcinomaAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDecision MakingHumansLung NeoplasmsQuinazolinesGenes, rasTreatment OutcomeDrug Resistance, Neoplasm
Funding
- CHEST Foundation
- LUNGevity Foundation
- AstraZeneca
- Memorial Sloan-Kettering Cancer Center
- Washington University in St. Louis
- Johns Hopkins University
- Strong
- National Institutes of Health
- Genentech
Citations
1,521
FWCI
79.03
field-weighted impact
References
15
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Clinical Cancer Research · 2006 · 901 citations
<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Cancer Research · 2006 · 2,215 citations
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer
BMC Cancer · 2006 · 292 citations
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Science Translational Medicine · 2012 · 1,320 citations
Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2008 · 3,144 citations
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Clinical Cancer Research · 2014 · 776 citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>
Journal of Clinical Oncology · 2009 · 1,873 citations
References
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences · 2004 · 4,332 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.